Wavesa | Wild-type vs. Alphab | Alpha vs. Deltab | Wild-type vs. Deltab | ||||
---|---|---|---|---|---|---|---|
Wild-type n = 4,387 | Alpha n = 1,673 | Delta n = 1,273 | Difference % (95% CI) | Difference % (95% CI) | Difference % (95% CI) | ||
Age, years: | 75–79e | 70–74e | 65–69e | ||||
20–49 | 274 (6.2) | 129 (7.7) | 226 (17.8) | 1.5 (0 to 2.9) | 10.0 (7.6 to 12.5) | 11.5 (9.3 to 13.7) | |
50–64 | 631 (14.4) | 292 (17.5) | 326 (25.6) | 3.1 (1.0 to 5.2) | 8.2 (5.1 to 11.2) | 11.2 (8.6 to 13.8) | |
65–79 | 1931 (44.0) | 709 (42.4) | 423 (33.2) | −1.6 (− 4.4 to 1.1) | −9.2 (− 12.7 to − 5.6) | −10.8 (− 13.8 to − 7.8) | |
80+ | 1,551 (35.4) | 543 (32.5) | 298 (23.4) | −2.9 (− 5.6 to − 0.2) | −9.0 (− 12.3 to − 5.8) | −11.9 (− 14.7 to − 9.2) | |
Sex, male | 2,558 (58.3) | 962 (57.5) | 661 (51.9) | −0.8 (− 3.6 to 2.0) | −5.6 (− 9.2 to − 2.0) | −6.4 (− 9.5 to − 3.3) | |
Comorbidity: | |||||||
Cerebrovascular disease | 1,133 (25.8) | 394 (23.6) | 219 (17.2) | −2.3 (− 4.7 to 0.1) | −6.3 (− 9.3 to − 3.4) | −8.6 (− 11.1 to − 6.2) | |
Malignancy | 1,482 (33.8) | 508 (30.4) | 364 (28.6) | −3.4 (− 6.0 to − 0.8) | −1.8 (− 5.1 to 1.5) | −5.2 (− 8.0 to − 2.3) | |
Renal disease | 662 (15.1) | 221 (13.2) | 169 (13.3) | −1.9 (− 3.8 to 0.1) | 0.1 (− 2.4 to 2.5) | −1.8 (− 4.0 to 0.3) | |
Congestive heart failure | 1906 (43.4) | 681 (40.7) | 455 (35.7) | −2.7 (− 5.5 to 0) | −5.0 (− 8.5 to − 1.4) | −7.7 (− 10.7 to − 4.7) | |
Liver disease | 1,210 (27.6) | 445 (26.6) | 308 (24.2) | −1.0 (− 3.5 to 1.5) | −2.4 (− 5.6 to 0.8) | −3.4 (− 6.1 to − 0.7) | |
Diabetes mellitus | 2,415 (55.0) | 896 (53.6) | 651 (51.1) | −1.5 (− 4.3 to 1.3) | −2.4 (− 6.1 to 1.2) | −3.9 (− 7.0 to − 0.8) | |
LTOT before COVID-19 diagnosis | 383 (8.7) | 106 (6.3) | 79 (6.2) | −2.4 (− 3.8 to − 1.0) | −0.1 (− 1.9 to 1.6) | −2.5 (− 4.1 to − 1.0) | |
Treatment for COVID-19: | |||||||
Corticosteroidsc | 1,894 (43.2) | 752 (45.0) | 394 (31.0) | 1.8 (− 1.0 to 4.6) | −14.0 (− 17.5 to − 10.5) | −12.2 (− 15.2 to − 9.3) | |
Steroid pulsed | 480 (10.9) | 169 (10.1) | 60 (4.7) | −0.8 (− 2.6 to 0.9) | −5.4 (− 7.2 to − 3.5) | −6.2 (− 7.7 to − 4.7) | |
Tocilizumab | 150 (3.4) | 79 (4.7) | 47 (3.7) | 1.3 (0.2 to 2.5) | −1.0 (− 2.5 to 0.4) | 0.3 (− 0.9 to 1.4) | |
Baricitinib | 22 (0.5) | 96 (5.7) | 51 (4.0) | 5.2 (4.1 to 6.4) | −1.7 (− 3.3 to − 0.2) | 3.5 (2.4 to 4.6) | |
Heparin | 747 (17.0) | 266 (15.9) | 114 (9.0) | −1.1 (− 3.2 to 0.9) | −6.9 (− 9.3 to − 4.6) | −8.1 (− 10.0 to − 6.1) | |
Respiratory support care: | |||||||
Oxygen therapy | 2,116 (48.2) | 748 (44.7) | 374 (29.4) | −3.5 (− 6.3 to − 0.7) | −15.3 (− 18.8 to − 11.9) | −18.9 (− 21.8 to − 15.9) | |
High-flow nasal cannula | 248 (5.7) | 134 (8.0) | 57 (4.5) | 2.4 (0.9 to 3.8) | −3.5 (− 5.3 to − 1.8) | −1.2 (− 2.5 to 0.2) | |
Mechanical ventilation | 379 (8.6) | 103 (6.2) | 23 (1.8) | −2.5 (− 3.9 to − 1.1) | −4.4 (− 5.7 to − 3.0) | −6.8 (− 7.9 to − 5.7) | |
60-day mortality | 700 (16.0) | 244 (14.6) | 95 (7.5) | −1.4 (− 3.4 to 0.6) | −7.1 (− 9.3 to − 4.9) | −8.5 (− 10.3 to − 6.7) |